Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
MACK, which was up 17% during 2023, is a classic uncorrelated "discount to the sum-of-the-parts" play. It can be...
— Scott Klarquist
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Merrimack Pharmaceuticals
No other institutional pitches found for this ticker yet.
More institutional theses from Seven Corners Capital Management, LLC
Rocket Companies ($RKT) is a technology-driven real estate, mortgage lending, and financial services platform led by founder Dan Gilbert. Representing 6.3% of...
Genworth Financial ($GNW) is a diversified financial services holding company whose core value driver is an 80% controlling ownership stake in Enact Holdings ($ACT), a profitable private mortgage insurer. Representing 17.4% of...
Pershing Square Holdings ($PSHZF) is an investment holding company managed by Bill Ackman that holds concentrated positions in high-quality North American public companies. Representing 25.6% of...